Sanofi-aventis

Aventis Pharma S.a.

Aventis Pharma Deutschland, Gmbh

Sanofi-a Ventis Deutschland Gmbh

Sanofi

Günter Müller

Stefan Petry

Gerhard Zoller

Karl Schoenafinger

Hans Matter

Markus Follmann

Hubert Heuer

David William Will

Georg Tschank

Paul Habermann

Karl-Heinz Baringhaus

Norbert Tennagels

Ulrich Werner

Gerhard Seipke

Anke Steinmetz

Armin Bauer

Swen Hoelder

Ingrid Sassoon

Mark Sommerfeld

Manfred Seidel

Christine Delaisi

Cécile Combeau

Roland Kurrle

The invention relates to carbamoylbenzotriazole derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments. 

Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases

The invention relates to triazolopyridine derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments. 

Triazolopyridine derivatives as inhibitors of lipases and phospholipases

Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, Rand Rare detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals.  These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).

4-benzimidazol-2-ylpyridazin-3-one derivatives

A substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-one, compound of formula 1,wherein R, R, R, Rand Rare as defined herein, pharmaceutical composition comprising the compound and use of the compound for inhibiting pancreatic lipase, or the prophylaxis or treatment of obesity are described.

Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof

Growing community of inventors

Frankfurt am Main, Germany

Günter Müller